Select the right BTK inhibitors and right dose regimen/frequency to treat CLL/non-Hodgkin
Select the right BTK inhibitors and right dose regimen/frequency to treat CLL/non-Hodgkin

-
Identify a patient’s unique BTK mutation status See Data
Identify a patient’s unique BTK mutation status See Data
-
On-target engagement with the right drug to determine the %BTK occupancy of a drug and its active metabolites in blood cells See Data
On-target engagement with the right drug to determine the %BTK occupancy of a drug and its active metabolites in blood cells See Data
-
Select treatment by determining appropriate dosing level & frequency to achieve a clinical response See Data
Select treatment by determining appropriate dosing level & frequency to achieve a clinical response See Data
-
Monitor drug off-target effects to define dosing regimens & reduce safety risks See Data
Monitor drug off-target effects to define dosing regimens & reduce safety risks See Data
Improve and balance clinical response and drug safety for leukemia and non-Hodgkin’s lymphoma patients
Improve and balance clinical response and drug safety for leukemia and non-Hodgkin’s lymphoma patients
Nextcea uses advanced LC-MS/MS platforms to identify and quantitate patients’ BTK mutation status, BTK inhibitor %occupancy and off-target effects.
Nextcea uses advanced LC-MS/MS platforms to identify and quantitate patients’ BTK mutation status, BTK inhibitor %occupancy and off-target effects.
Our clinical blood assays allow physicians and pharmaceutical sponsors to:
Our clinical blood assays allow physicians and pharmaceutical sponsors to:
-
Select the “right” treatment for cancer patients based on their BTK mutation status (covalent vs. non-covalent drugs or combination of both).
Select the “right” treatment for cancer patients based on their BTK mutation status (covalent vs. non-covalent drugs or combination of both).
-
Evaluate dosing requirements for patients based the %occupancy of BTK inhibitors and active metabolites
Evaluate dosing requirements for patients based the %occupancy of BTK inhibitors and active metabolites
-
Reduce safety risks associated with the off-target effects of BTK inhibitors (ex. bleeding associated with ibrutinib).
Reduce safety risks associated with the off-target effects of BTK inhibitors (ex. bleeding associated with ibrutinib).
Advanced UPLC-MS/MS Services
Advanced UPLC-MS/MS Services
-
Identify and profile the percentage of functional BTK C481 mutations in patients over time
Identify and profile the percentage of functional BTK C481 mutations in patients over time
-
Absolutely quantitate the target %occupancy of BTK inhibitors (ex. ibrutinib, acalabrutinib, zanubrutinib) in patients’ white blood cells.
Absolutely quantitate the target %occupancy of BTK inhibitors (ex. ibrutinib, acalabrutinib, zanubrutinib) in patients’ white blood cells.
-
Correlate the %occupancy associated with clinical response (ex. the change in white blood cell count) in individual patients
Correlate the %occupancy associated with clinical response (ex. the change in white blood cell count) in individual patients